Boston Scientific director granted deferred stock units

Boston Scientific director Cheryl Pegus reported an equity award in the form of deferred stock units.

Rhea-AI Filing Summary

Boston Scientific director Cheryl Pegus reported an equity award in the form of deferred stock units. On March 2, 2026, she acquired 24 deferred stock units at a stated price of $0.00 per unit, reflecting $1,845.25 of compensation based on the common stock’s closing price that day.

Each deferred stock unit represents a commitment by Boston Scientific to issue one share of common stock in the future. These units were granted in lieu of 50% of her yearly cash compensation, vest in full at the next annual stockholder meeting, and the underlying shares will be delivered after she leaves the Board under the company’s non-employee director deferred compensation plan. Following this grant, her reported direct holdings total 5,917 deferred stock units.

Insider Trade Summary

Grant/Award: 24 shares

Grant/Award 1 txn

Insider Pegus Cheryl

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Deferred Stock Units	24	$0.00	$0.00

Holdings After Transaction: Deferred Stock Units — 5,917 contracts (Direct)

Footnotes (2)

1. F1. Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.
2. F2. Deferred stock units granted in lieu of 50% yearly cash compensation, vesting in full upon the next annual meeting of stockholders. Vested shares of stock will be issued to the reporting person following the reporting person's separation from Board of Directors service in accordance with the Company's Non-Employee Director Deferred Compensation Plan. Reflects a value of $1,845.25, divided by the closing price of the common stock on the date of grant.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Boston Scientific (BSX) director Cheryl Pegus report?

Cheryl Pegus reported an acquisition of 24 deferred stock units as director compensation. The award reflects $1,845.25 of value, calculated using Boston Scientific’s common stock closing price on the March 2, 2026 grant date and increases her total deferred stock units to 5,917.

How do the Boston Scientific (BSX) deferred stock units reported by Cheryl Pegus work?

Each deferred stock unit represents a future right to receive one share of Boston Scientific common stock. The units are granted as non-cash director compensation, vest at the next annual stockholder meeting, and convert into shares only after the director’s separation from Board service under the company’s deferred compensation plan.

What is the value of the deferred stock units granted to Boston Scientific (BSX) director Cheryl Pegus?

The 24 deferred stock units granted to Cheryl Pegus reflect a value of $1,845.25. This value is determined by dividing $1,845.25 by the closing price of Boston Scientific common stock on the March 2, 2026 grant date, as described in the footnotes.

How many deferred stock units does Boston Scientific (BSX) director Cheryl Pegus hold after this Form 4?

After this reported transaction, Cheryl Pegus holds 5,917 deferred stock units directly. This total includes the newly granted 24 units and represents Boston Scientific’s commitment to issue an equal number of common shares to her in the future, subject to plan terms.

Why did Boston Scientific (BSX) grant deferred stock units instead of cash to Cheryl Pegus?

The filing states that deferred stock units were granted in lieu of 50% of Cheryl Pegus’s yearly cash compensation as a director. This structure provides equity-based compensation that aligns director interests with shareholders, with vesting at the next annual meeting and stock delivery after Board service ends.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/04/2026 - 07:35 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Pegus Cheryl

(Last) (First) (Middle)

300 BOSTON SCIENTIFIC WAY

(Street)

MARLBOROUGH MA 01752-1234

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BOSTON SCIENTIFIC CORP [ BSX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Deferred Stock Units	(1)	03/02/2026		A		24		(2)	(2)	Common Stock	24	$0.0000	5,917	D

Explanation of Responses:

1. Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

2. Deferred stock units granted in lieu of 50% yearly cash compensation, vesting in full upon the next annual meeting of stockholders. Vested shares of stock will be issued to the reporting person following the reporting person's separation from Board of Directors service in accordance with the Company's Non-Employee Director Deferred Compensation Plan. Reflects a value of $1,845.25, divided by the closing price of the common stock on the date of grant.

	/s/ Susan Thompson, Attorney-in-Fact	03/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.